XNYS
BLCO
Market cap5.96bUSD
Jul 09, Last price
16.73USD
1D
0.42%
1Q
1.46%
IPO
-7.06%
Name
Bausch + Lomb Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bausch + Lomb Corporation is a global leader in eye health, delivering a wide range of products and services across the world. Its business is divided into three key areas: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care sector offers an extensive selection of contact lenses, covering options from daily disposables to frequently replaced types, in addition to lens care solutions, non-prescription eye drops, and vitamin and mineral supplements designed to alleviate conditions such as eye allergies, conjunctivitis, and dry eye. Within the Ophthalmic Pharmaceuticals division, the company develops and markets both proprietary and generic medications for post-operative recovery and the management of ophthalmic conditions like glaucoma, ocular hypertension, and retinal diseases, alongside therapeutic contact lenses. Finally, the Surgical segment equips medical professionals with advanced tools and technologies for cataract, vitreous, and retinal treatments, including intraocular lenses with their specialized delivery systems, phacoemulsification apparatus, and other essential surgical instruments. Founded in 1853, Bausch + Lomb's headquarters are situated in Vaughan, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||